Valuation : Nuvectra Corporation

Market Cap 1.7M 1.46M 1.37M 1.25M 2.34M 161M 2.35M 16.28M 6.3M 82.33M 6.38M 6.24M 262M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -45.96M -43.24M -39.46M -73.64M -5.07B -74.02M -512M -198M -2.59B -201M -196M -8.24B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 2019-01-30
Compliance Officer 51 2014-12-31
Director TitleAgeSince
Director/Board Member 67 2016-02-29
Director/Board Member 78 2016-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
+0.75%-3.81%-19.47%+3.72% 183B
+0.25%+0.62%-1.40%+13.94% 118B
-0.00%-3.12%+9.11%+83.35% 61.96B
-0.49%-6.75%+11.83%+44.52% 50.6B
+1.23%-3.87%-5.37%-32.53% 48.78B
-0.06%-5.23%+8.41%-20.78% 31.9B
-0.55%-4.09% - - 30.44B
+0.29%-1.11%+34.44%-14.68% 23.77B
-2.51%-10.87%-14.66%+6.30% 22.26B
Average -0.13%-0.79%+2.86%+10.48% 57.05B
Weighted average by Cap. +0.18%-1.89%-3.81%+13.49%

Financials

2017 2018
Net sales 31.84M 27.37M 25.75M 23.5M 43.86M 3.02B 44.08M 305M 118M 1.54B 120M 117M 4.91B 48.83M 41.98M 39.5M 36.05M 67.27M 4.63B 67.62M 468M 181M 2.37B 183M 179M 7.53B
Net income -44.6M -38.35M -36.08M -32.92M -61.44M -4.23B -61.76M -427M -165M -2.16B -167M -164M -6.88B -48.13M -41.38M -38.93M -35.53M -66.3M -4.56B -66.65M -461M -178M -2.33B -181M -177M -7.42B
Net Debt -1.49M -1.28M -1.21M -1.1M -2.05M -141M -2.06M -14.28M -5.52M -72.2M -5.6M -5.47M -230M -55.16M -47.42M -44.62M -40.72M -75.98M -5.23B -76.38M -529M -205M -2.67B -207M -203M -8.51B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!